Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Julie Schmidt » Publikationer » Clonal hematopoiesis and risk of prostate cancer in large...

Om AU

Julie Schmidt

Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

DOI

  • Anqi Wang, University of Southern California
    • ,
  • Yili Xu, University of Southern California
    • ,
  • Yao Yu, University of Texas MD Anderson Cancer Center
    • ,
  • Kevin T. Nead, University of Texas MD Anderson Cancer Center
    • ,
  • Tae Beom Kim, University of Texas MD Anderson Cancer Center
    • ,
  • Keren Xu, University of Southern California
    • ,
  • Tokhir Dadaev, Institute of Cancer Research
    • ,
  • Ed Saunders, Institute of Cancer Research
    • ,
  • Xin Sheng, University of Southern California
    • ,
  • Peggy Wan, University of Southern California
    • ,
  • Loreall Pooler, University of Southern California
    • ,
  • Lucy Y. Xia, University of Southern California
    • ,
  • Stephen Chanock, National Institutes of Health
    • ,
  • Sonja I. Berndt, National Institutes of Health
    • ,
  • Susan M. Gapstur, American Cancer Society
    • ,
  • Victoria Stevens, American Cancer Society
    • ,
  • Demetrius Albanes, National Institutes of Health
    • ,
  • Stephanie J. Weinstein, National Institutes of Health
    • ,
  • Vincent Gnanapragasam, Department of Surgery
    • ,
  • Graham G. Giles, Cancer Council Victoria, Monash University, University of Melbourne
    • ,
  • Tu Nguyen-Dumont, Monash University, University of Melbourne
    • ,
  • Roger L. Milne, Cancer Council Victoria, Monash University, University of Melbourne
    • ,
  • Mark M. Pomerantz, Dana-Farber Cancer Institute
    • ,
  • Julie A. Schmidt
  • Konrad H. Stopsack, Harvard University
    • ,
  • Lorelei A. Mucci, Harvard University
    • ,
  • William J. Catalona, Northwestern University
    • ,
  • Kurt N. Hetrick, Johns Hopkins University
    • ,
  • Kimberly F. Doheny, Johns Hopkins University
    • ,
  • Robert J. MacInnis, Cancer Council Victoria, University of Melbourne
    • ,
  • Melissa C. Southey, Cancer Council Victoria, Monash University, University of Melbourne
    • ,
  • Rosalind A. Eeles, National Institutes of Health, Royal Marsden NHS Foundation Trust
    • ,
  • Fredrik Wiklund, Karolinska Institutet
    • ,
  • Zsofia Kote-Jarai, Institute of Cancer Research
    • ,
  • Adam J. de Smith, University of Southern California
    • ,
  • David V. Conti, University of Southern California
    • ,
  • Chad Huff, University of Texas MD Anderson Cancer Center
    • ,
  • Christopher A. Haiman, University of Southern California
    • ,
  • Burcu F. Darst, Fred Hutchinson Cancer Research Center

Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate cancer, the fifth leading cause of cancer death of men worldwide. We evaluated the association of age-related CHIP with overall and aggressive prostate cancer risk in two large whole-exome sequencing studies of 75 047 European ancestry men, including 7663 prostate cancer cases, 2770 of which had aggressive disease, and 3266 men carrying CHIP variants. We found that CHIP, defined by over 50 CHIP genes individually and in aggregate, was not significantly associated with overall (aggregate HR = 0.93, 95% CI = 0.76-1.13, P = 0.46) or aggressive (aggregate OR = 1.14, 95% CI = 0.92-1.41, P = 0.22) prostate cancer risk. CHIP was weakly associated with genetic risk of overall prostate cancer, measured using a polygenic risk score (OR = 1.05 per unit increase, 95% CI = 1.01-1.10, P = 0.01). CHIP was not significantly associated with carrying pathogenic/likely pathogenic/deleterious variants in DNA repair genes, which have previously been found to be associated with aggressive prostate cancer. While findings from this study suggest that CHIP is likely not a risk factor for prostate cancer, it will be important to investigate other types of CH in association with prostate cancer risk.

OriginalsprogEngelsk
TidsskriftHuman Molecular Genetics
Vol/bind32
Nummer3
Sider (fra-til)489-495
Antal sider7
ISSN0964-6906
DOI
StatusUdgivet - jan. 2023

Se relationer på Aarhus Universitet Citationsformater

ID: 315477516